Latest From Pharmstandard OJSC
The healthcare giant is investing heavily into partnerships designed to beat the two infectious diseases.
Johnson & Johnson maintains its game-changing antibiotic bedaquiline for drug-resistant tuberculosis is priced "fairly" at $400 for a six-month course, and terms calls by public health advocates to cut the cost to $1 a day “not realistic.”
Lilly is the latest established biopharma to license Halozyme's EXTENZE subcutaneous delivery technology. Mallinckrodt pays $175m up front to The Medicines Co. for a trio of topical hemostasis drugs.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.
- Therapeutic Areas
- OJSC Pharmstandard
- Biovit LLC
- Eastern Europe
- Parent & Subsidiaries
- Pharmstandard OJSC
- Senior Management
Vladimir Chupikov , CEO
Marina Markova , CFO
- Contact Info
Phone: 495 970 00 30
5 ‘B’ Likhachevsky proezd
Dolgoprudny, Moscow Region, 141700
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.